Focused on novel dermatology products and technology platforms in the key therapeutic areas of fungal infection, eczema/dermatitis and psoriasis York Pharma is a recently established specialised pharmaceutical company.

York Pharma (UK) Ltd was founded in 2003, and having floated in April 2004 on the Alternative Investment Market (AIM) of the London Stock Exchange, York Pharma Plc has developed rapidly with 3 sites in the UK, and offices in Germany (York Pharma GmbH) and Japan (York Pharma KK). In February 2005 York Pharma Plc acquired the Sheffield-based Molecular SkinCare Ltd.

MSL was established within the division of Genomic Medicine, University of Sheffield Medical School in 2001 and now operates as York Pharma (R&D) Ltd, the research and Development site for the Parent Company.

The company provides novel therapeutic strategies from the new drug discovery to improved methods of diagnosis in therapy areas embracing approximately 75% of the overall value of the dermatology market thereby enabling York Pharma to emerge as a leading international dermatology company.

In July 2005 York Pharma filed its first marketing authorisation application in Europe for Abasol™. Abasol ™ is a new chemical formula intended for the topical prescription antifungal market.

York Pharma is in the process of developing a product for the treatment and prevention of flares of eczema and irritant contact dermatitis, which has arisen out of the Company’s Skin Barrier Repair Technology Platform.

The Company has progressed development of a new class of drugs for the topical treatment of Psoriasis, Vitamin A Metabolic Pathway (VAMP) inhibitors, with their lead compound in clinical development.

York Pharma have patented a novel drug target with potential use in oncology and intends to characterise the importance of the drug target for the treatment of skin and other cancers in the future.